Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pattern Electroretinogram in Glaucoma Suspects with Signs of Conversion: Diagnosis, Assessment, and Monitoring Treatment - Case Report.

Case reports in ophthalmology·2026
Same author

Foveal Avascular Zone Enlargement as a Risk Factor for Early Retinal Ganglion Cell Dysfunction in Glaucoma Suspects.

Diagnostics (Basel, Switzerland)·2025
Same author

Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Patients With Open Angle Glaucoma: A Systematic Review and Meta-analysis.

Journal of glaucoma·2025
Same author

Novel Structure-Function Models for Estimating Retinal Ganglion Cell Count Using Pattern Electroretinography in Glaucoma Suspects.

Diagnostics (Basel, Switzerland)·2025
Same author

Retinal Vessel Diameter Reductions Are Associated with Retinal Ganglion Cell Dysfunction, Thinning of the Ganglion Cell and Inner Plexiform Layers, and Decreased Visual Field Global Indices in Glaucoma Suspects.

Diagnostics (Basel, Switzerland)·2025
Same author

Diagnostic Capability of Pattern Electroretinogram and Three Circumpapillary Retinal Nerve Fiber Layer Thickness Circle Diameter Scans in Glaucoma Suspects.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same journal

Reply to Comment on Visual Field Progression in Glaucoma Patients with Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Comment on: "Safety and efficiency reducing retinopathy of prematurity guideline sensitivity: an external validation using a large US-based dataset".

American journal of ophthalmology·2026
Same journal

Reply to Comment on "Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease".

American journal of ophthalmology·2026
Same journal

Comment on: Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Corneal sensitivity changes and nerve plexus abnormalities in noninfectious anterior uveitis.

American journal of ophthalmology·2026
Same journal

Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates.

American journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Sequential glaucoma implants in refractory glaucoma.

Aashish Anand1, Celso Tello, Paul A Sidoti

  • 1New York Eye and Ear Infirmary, New York, New York, USA.

American Journal of Ophthalmology
|October 20, 2009
PubMed
Summary
This summary is machine-generated.

A second glaucoma implant effectively lowers intraocular pressure (IOP) in patients with refractory glaucoma. This procedure significantly reduces medication needs and maintains visual acuity, offering a viable option for advanced cases.

Related Experiment Videos

Last Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Medical Devices

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Intraocular pressure (IOP) is a primary modifiable risk factor for glaucoma progression.
  • Previous glaucoma implant surgery may fail to achieve adequate IOP control.

Purpose of the Study:

  • To assess the efficacy of a second glaucoma implant in patients with prior surgery and uncontrolled IOP.
  • To evaluate the impact on IOP, medication use, visual acuity, and complications.

Main Methods:

  • Retrospective observational cohort study.
  • Included 43 eyes of patients who underwent a second glaucoma implant surgery between 1996 and 2008.
  • Success defined by IOP < 21 mmHg or < 17 mmHg, with >25% IOP reduction and no hypotony.

Main Results:

  • High success rates observed: 93% (IOP < 21 mmHg) and 83% (IOP < 17 mmHg) at 1 year.
  • Significant IOP reduction from 24.7 mmHg to 13.6 mmHg (P < .001).
  • Mean medication use decreased from 3.9 to 1.4 (P < .001); visual acuity remained stable.

Conclusions:

  • A second glaucoma implant is an effective surgical option for refractory glaucoma.
  • It provides significant IOP lowering and reduces medication burden.
  • The procedure demonstrates favorable safety and efficacy in the long term.